Assertio Operating Income from 2010 to 2026

ASRT Stock

USD 12.06 0.19 1.60%

Assertio Therapeutics Operating Income yearly trend continues to be comparatively stable with very little volatility. Operating Income will likely drop to about -23.1 M in 2026. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Assertio Therapeutics generates from its operations. View All Fundamentals

Operating Income

First Reported

1997-03-31

Previous Quarter

-8 M

Current Value

11.5 M

Quarterly Volatility

35 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Interest Hikes

Check Assertio Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Assertio Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 3.3 M, Total Revenue of 128.4 M or Gross Profit of 112.1 M, as well as many indicators such as Price To Sales Ratio of 0.73, Dividend Yield of 0.0 or PTB Ratio of 0.59. Assertio financial statements analysis is a perfect complement when working with Assertio Therapeutics Valuation or Volatility modules.

Build AI portfolio with Assertio Stock

Check out the analysis of Assertio Therapeutics Correlation against competitors.

For more information on how to buy Assertio Stock please use our How to Invest in Assertio Therapeutics guide.

The evolution of Operating Income for Assertio Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Assertio Therapeutics compares to historical norms and industry peers.

Latest Assertio Therapeutics' Operating Income Growth Pattern

Below is the plot of the Operating Income of Assertio Therapeutics over the last few years. Operating Income is the amount of profit realized from Assertio Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Assertio Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Assertio Therapeutics' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Assertio Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

Assertio Operating Income Regression Statistics

	Arithmetic Mean	(16,432,954)
	Geometric Mean	33,778,275
	Coefficient Of Variation	(629.92)
	Mean Deviation	66,445,839
	Median	(22,028,400)
	Standard Deviation	103,514,851
	Sample Variance	10715.3T
	Range	480.4M
	R-Value	(0.36)
	Mean Square Error	9924.7T
	R-Squared	0.13
	Significance	0.15
	Slope	(7,438,398)
	Total Sum of Squares	171445.2T

Assertio Operating Income History

	2026	-23.1 M
	2025	-22 M
	2024	-24.5 M
	2023	-243.5 M
	2022	39.4 M
	2021	9.4 M
	2020	-82.2 M

Other Fundumenentals of Assertio Therapeutics

Non Operating Income Net Other

Assertio Therapeutics Operating Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Short Term Investments	Common Stock	Long Term Debt	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Long Term Investments	Intangible Assets	Capital Surpluse	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.74	0.74	0.36	0.6	0.7	0.98	0.57	0.85	0.37	0.58	0.96	0.87	0.61	-0.83	-0.21	0.93	-0.23	0.88	0.63	0.44	-0.34	-0.27
Total Stockholder Equity	0.74		0.22	0.38	0.57	0.45	0.6	0.85	0.71	0.54	0.5	0.63	0.56	0.52	-0.29	-0.29	0.51	-0.2	0.52	0.5	0.35	-0.13	-0.34
Net Debt	0.74	0.22		0.11	0.4	0.63	0.82	-0.09	0.6	0.06	0.23	0.86	0.65	0.39	-0.97	0.05	0.92	-0.02	0.84	0.44	0.24	-0.25	-0.11
Retained Earnings	0.36	0.38	0.11		0.28	-0.29	0.33	0.35	0.5	0.3	0.69	0.38	0.58	-0.05	-0.15	0.55	0.28	-0.87	0.25	0.69	0.92	-0.86	-0.61
Accounts Payable	0.6	0.57	0.4	0.28		0.38	0.55	0.41	0.76	0.67	0.36	0.62	0.44	0.46	-0.43	-0.08	0.53	-0.19	0.64	0.76	0.21	-0.18	-0.08
Net Receivables	0.7	0.45	0.63	-0.29	0.38		0.71	0.29	0.57	0.29	0.21	0.68	0.43	0.75	-0.67	-0.51	0.69	0.27	0.76	0.22	-0.21	0.26	0.15
Total Liab	0.98	0.6	0.82	0.33	0.55	0.71		0.44	0.82	0.29	0.55	0.97	0.88	0.58	-0.91	-0.17	0.97	-0.21	0.91	0.6	0.43	-0.37	-0.22
Total Current Assets	0.57	0.85	-0.09	0.35	0.41	0.29	0.44		0.55	0.56	0.55	0.41	0.47	0.49	-0.04	-0.31	0.25	-0.28	0.26	0.37	0.34	-0.16	-0.15
Short Term Debt	0.85	0.71	0.6	0.5	0.76	0.57	0.82	0.55		0.65	0.62	0.88	0.77	0.55	-0.65	0.0	0.78	-0.4	0.85	0.88	0.49	-0.43	-0.27
Short Term Investments	0.37	0.54	0.06	0.3	0.67	0.29	0.29	0.56	0.65		0.54	0.36	0.3	0.28	-0.07	0.08	0.19	-0.37	0.42	0.7	0.3	-0.08	-0.06
Common Stock	0.58	0.5	0.23	0.69	0.36	0.21	0.55	0.55	0.62	0.54		0.55	0.71	0.37	-0.34	0.2	0.44	-0.83	0.5	0.68	0.77	-0.64	-0.42
Long Term Debt	0.96	0.63	0.86	0.38	0.62	0.68	0.97	0.41	0.88	0.36	0.55		0.85	0.6	-0.89	-0.05	0.97	-0.26	0.93	0.68	0.46	-0.4	-0.25
Property Plant Equipment	0.87	0.56	0.65	0.58	0.44	0.43	0.88	0.47	0.77	0.3	0.71	0.85		0.36	-0.76	-0.06	0.83	-0.5	0.77	0.68	0.68	-0.58	-0.3
Current Deferred Revenue	0.61	0.52	0.39	-0.05	0.46	0.75	0.58	0.49	0.55	0.28	0.37	0.6	0.36		-0.47	-0.41	0.54	0.05	0.52	0.23	-0.09	-0.07	0.15
Net Tangible Assets	-0.83	-0.29	-0.97	-0.15	-0.43	-0.67	-0.91	-0.04	-0.65	-0.07	-0.34	-0.89	-0.76	-0.47		0.08	-0.97	0.08	-0.87	-0.48	-0.28	0.33	0.13
Long Term Investments	-0.21	-0.29	0.05	0.55	-0.08	-0.51	-0.17	-0.31	0.0	0.08	0.2	-0.05	-0.06	-0.41	0.08		-0.1	-0.59	-0.08	0.3	0.56	-0.5	-0.3
Intangible Assets	0.93	0.51	0.92	0.28	0.53	0.69	0.97	0.25	0.78	0.19	0.44	0.97	0.83	0.54	-0.97	-0.1		-0.16	0.92	0.58	0.38	-0.36	-0.23
Capital Surpluse	-0.23	-0.2	-0.02	-0.87	-0.19	0.27	-0.21	-0.28	-0.4	-0.37	-0.83	-0.26	-0.5	0.05	0.08	-0.59	-0.16		-0.2	-0.67	-0.9	0.77	0.51
Long Term Debt Total	0.88	0.52	0.84	0.25	0.64	0.76	0.91	0.26	0.85	0.42	0.5	0.93	0.77	0.52	-0.87	-0.08	0.92	-0.2		0.69	0.34	-0.22	-0.2
Short Long Term Debt	0.63	0.5	0.44	0.69	0.76	0.22	0.6	0.37	0.88	0.7	0.68	0.68	0.68	0.23	-0.48	0.3	0.58	-0.67	0.69		0.68	-0.58	-0.37
Net Invested Capital	0.44	0.35	0.24	0.92	0.21	-0.21	0.43	0.34	0.49	0.3	0.77	0.46	0.68	-0.09	-0.28	0.56	0.38	-0.9	0.34	0.68		-0.81	-0.59
Net Working Capital	-0.34	-0.13	-0.25	-0.86	-0.18	0.26	-0.37	-0.16	-0.43	-0.08	-0.64	-0.4	-0.58	-0.07	0.33	-0.5	-0.36	0.77	-0.22	-0.58	-0.81		0.47
Capital Stock	-0.27	-0.34	-0.11	-0.61	-0.08	0.15	-0.22	-0.15	-0.27	-0.06	-0.42	-0.25	-0.3	0.15	0.13	-0.3	-0.23	0.51	-0.2	-0.37	-0.59	0.47

Click cells to compare fundamentals

About Assertio Therapeutics Financial Statements

Assertio Therapeutics shareholders use historical fundamental indicators, such as Operating Income, to determine how well the company is positioned to perform in the future. Although Assertio Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Assertio Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Assertio Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Operating Income	-22 M	-23.1 M
Non Operating Income Net Other	34.9 M	36.6 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Assertio Stock Analysis

When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Assertio Operating Income from 2010 to 2026

Latest Assertio Therapeutics' Operating Income Growth Pattern

Assertio Operating Income Regression Statistics

Assertio Operating Income History

Other Fundumenentals of Assertio Therapeutics

Assertio Therapeutics Operating Income component correlations

About Assertio Therapeutics Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Assertio Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY